BHVN
Price
$17.14
Change
-$1.53 (-8.19%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
1.91B
29 days until earnings call
RCKT
Price
$4.93
Change
-$0.47 (-8.70%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
574.73M
32 days until earnings call
Ad is loading...

BHVN vs RCKT

Header iconBHVN vs RCKT Comparison
Open Charts BHVN vs RCKTBanner chart's image
Biohaven
Price$17.14
Change-$1.53 (-8.19%)
Volume$11.6K
Capitalization1.91B
Rocket Pharmaceuticals
Price$4.93
Change-$0.47 (-8.70%)
Volume$87.97K
Capitalization574.73M
BHVN vs RCKT Comparison Chart
Loading...
BHVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BHVN vs. RCKT commentary
Apr 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHVN is a Hold and RCKT is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 11, 2025
Stock price -- (BHVN: $18.67 vs. RCKT: $5.39)
Brand notoriety: BHVN and RCKT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BHVN: 216% vs. RCKT: 310%
Market capitalization -- BHVN: $1.91B vs. RCKT: $574.73M
BHVN [@Biotechnology] is valued at $1.91B. RCKT’s [@Biotechnology] market capitalization is $574.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $281.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHVN’s FA Score shows that 0 FA rating(s) are green whileRCKT’s FA Score has 1 green FA rating(s).

  • BHVN’s FA Score: 0 green, 5 red.
  • RCKT’s FA Score: 1 green, 4 red.
According to our system of comparison, RCKT is a better buy in the long-term than BHVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHVN’s TA Score shows that 4 TA indicator(s) are bullish while RCKT’s TA Score has 4 bullish TA indicator(s).

  • BHVN’s TA Score: 4 bullish, 4 bearish.
  • RCKT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both BHVN and RCKT are a good buy in the short-term.

Price Growth

BHVN (@Biotechnology) experienced а -21.16% price change this week, while RCKT (@Biotechnology) price change was -14.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.53%. For the same industry, the average monthly price growth was -18.05%, and the average quarterly price growth was -19.90%.

Reported Earning Dates

BHVN is expected to report earnings on Aug 04, 2025.

RCKT is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (-7.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BHVN($1.91B) has a higher market cap than RCKT($575M). BHVN YTD gains are higher at: -50.013 vs. RCKT (-57.120). RCKT has higher annual earnings (EBITDA): -247.48M vs. BHVN (-877.26M). BHVN has more cash in the bank: 486M vs. RCKT (372M). RCKT has less debt than BHVN: RCKT (25.5M) vs BHVN (36.6M). BHVN (0) and RCKT (0) have equivalent revenues.
BHVNRCKTBHVN / RCKT
Capitalization1.91B575M331%
EBITDA-877.26M-247.48M354%
Gain YTD-50.013-57.12088%
P/E RatioN/AN/A-
Revenue00-
Total Cash486M372M131%
Total Debt36.6M25.5M144%
FUNDAMENTALS RATINGS
BHVN vs RCKT: Fundamental Ratings
BHVN
RCKT
OUTLOOK RATING
1..100
5963
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
9797
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (28) in the Biotechnology industry is in the same range as BHVN (56) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to BHVN’s over the last 12 months.

RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to BHVN’s over the last 12 months.

RCKT's SMR Rating (94) in the Biotechnology industry is in the same range as BHVN (97) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to BHVN’s over the last 12 months.

RCKT's Price Growth Rating (97) in the Biotechnology industry is in the same range as BHVN (97) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to BHVN’s over the last 12 months.

RCKT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to BHVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHVNRCKT
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 18 days ago
75%
Bullish Trend 18 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
BHVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MNDIX24.69N/A
N/A
MFS New Discovery I
RCSIX11.05N/A
N/A
RBC Small Cap Core I
JNBCX9.20N/A
N/A
JPMorgan Income Builder C
IEMHX8.56N/A
N/A
Voya Multi-Manager Emerging Markets Eq A
AMTZX8.31N/A
N/A
AB All Market Real Return Z